The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.
Inscripta is creating its own market and customer base while also utilizing the expertise of its customers to refine and improve its products.
California Kids Cancer Comparison leader David Haussler said the project's workflow was able to match 100 percent of tumor samples it tested to possible treatments.
There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.
A look back at the trends, scientific breakthroughs, business deals, and patent battles of genome editing technology from 2017 reveals a rapidly evolving field.
The Liu lab found a way to make edits without causing double-strand DNA breaks while the Zhang lab created an RNA editor that doesn't permanently alter the genome.
The perturbed genes will be identified by barcodes associated with single guide RNAs, and read using an in situ sequencing method.
The gift will support work being done by Atul Butte using publicly availably health data to gain new insights on disease.
As the development of drugs and diagnostics are increasingly beginning to merge, Covance is aiming to dedicate resources to capture market share.
The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.
The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.
A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.
Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.
In Science this week: analysis of DNA from ancient North Africans, and more.